The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Practice-changing advances in DLBCL immunotherapy in 2026
Joshua Brody, MD, The Tisch Cancer Institute at Mount Sinai, New York City, NY, provides insight into the most practice-changing advances in diffuse large B-cell lymphoma (DLBCL) immunotherapy in 2026, highlighting the EPCORE NHL-6 trial (NCT05451810), which demonstrated the feasibility of outpatient administration of epcoritamab. Dr Brody notes that this will have a significant impact on the management of DLBCL by community oncologists, and anticipates that upcoming frontline trial results may lead to the approval of epcoritamab plus R-CHOP in the frontline setting. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
